Humanitas Catania
- Address
- Via Contrada Gubba 11, Catania, Italy
Humanitas Catania - Oncology and Hematology Research Center
Humanitas Catania is a specialized clinical research facility focused on advancing treatment strategies for complex hematological malignancies and solid tumors. The center demonstrates particular expertise in investigating targeted therapies and precision medicine approaches for patients with cancer.
- Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma with autoimmune complications
- Advanced non-small-cell lung cancer with EGFR mutations
- Targeted therapy sequencing and optimization strategies
The research team at Humanitas Catania conducts innovative trials exploring tyrosine kinase inhibitors and BTK inhibitors for both rare autoimmune manifestations in hematologic disorders and molecularly-defined lung cancer populations. Their work includes studies on EGFR-TKI sequencing and the treatment of autoimmune hemolytic anemia in lymphoproliferative disorders, addressing critical unmet needs in oncology care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Humanitas Catania
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Dexamethasone Premedication to Prevent Grade ≥2 Interstitial Lung Disease in Breast Cancer Patients Receiving Trastuzumab Deruxtecan | Istituto Di Ricerche Farmacologiche Mario Negri | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dacomitinib | 1 | Unknown | 2020-03-10 | 2020-03-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.